Apoptosis and Bcl-2 expression in relation to age, tumor characteristics and prognosis in breast cancer

International Journal of Biological Markers

Volumn 14, Issue 2, 1999, Pages 84-91

  Holmqvist, P ^a   Lundstrom M ^a   Stål, Olle ^a   Arnesson, L G ^b   Nordenskjold B ^b   Nordenskjold K ^b   Malmstrom A ^b   Bang H ^b   Kallstrom A Ch ^b   Einarsson, E ^b   Norberg, B ^b   Adlouni, W ^b   Henning, A ^b   Sundquist, M ^b   Tejler, G ^b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b NONE

Author keywords

Age; Apoptosis; Bcl 2; Breast cancer; P53; Prognosis

Indexed keywords

DNA FRAGMENT; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGE; AGED; ANEUPLOIDY; APOPTOSIS; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST CARCINOMA; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; LYMPHOMA; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; SWEDEN;

EID: 0033066589     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089901400205     Document Type: Article

References (29)

1. Lipponen P, Aaltomaa S, Kosma V-M, Syrjænen K. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer 1994; 30A: 2068-73.
2. Sierra A, Lloveras B, Castellsagué X, Moreno L, Garcia-Ramirez M, Fabra A. Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int J Cancer 1995; 60: 54-60.
3. Bodis S, Siziopikou KP, Schnitt SJ, Harris JR, Fischer DE. Extensive apoptosis in ductal carcinoma in situ of the breast. Cancer 1996; 77: 1831-5.
4. Mustonen M, Raunio H, Pääkkö P, Soini Y. The extent of apoptosis is inversely associated with bcl-2 expression in premalignant and malignant breast lesions. Histopathology 1997; 31: 347-54.
5. Steck KD, McDonnell TJ, Sneige N, El-Naggar AK. Flow cytometric analysis of apoptosis and BCL-2 in primary breast carcinomas: Clinical and biological implications. Cytometry 1996; 24: 116-22.
6. Bhargava V, Kell DL, van de Rijn M, Warnke RA. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Path 1994; 145: 535-40.
7. Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G. The prevalence of Bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch 1994: 424: 47-51.
8. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long term survival in breast cancer. Am J Pathol 1994; 145: 1191-8.
9. Gorczyca W, Markiewski M, Kram A, Tuziak T, Domagala W. Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction. Virchows Arch 1995; 426: 229-33.
10. Gee JMW, Robertson JFR, Ellis IO, et al. Immunocytochemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1994; 59: 619-28.
11. Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, Van Marck E. Prognostic value of bcl-2 in invasive breast cancer. Br J Cancer 1995; 72: 354-60.
12. Kobayashi S, Iwase H, Ito Y, et al. Clinical significance of bcl-2 gene expression in human breast cancer tissues. Breast Cancer Res Treat 1997; 42: 173-81.
13. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. bcl-2 in normal human breast and carcinoma, association with estrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994; 69: 135-9.
14. Silvestrini R, Veneroni S, Daidone MG, et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994; 86: 499-504.
15. Lipponen P, Pietiläinen T, Kosma V-M, Aaltomaa S, Eskelinen M, Syrjänen K. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol 1995; 177: 49-55.
16. Stål O, Brisfors A, Carstensen J, Ferraud L, Hatschek T, Nordenskjöld B, The South-East Sweden Breast Cancer Group. Relationships of DNA ploidy, S-phase fraction and hormone receptor status to tumor stage in breast cancers detected by population screening. Int J Cancer 1992; 51: 28-33.
17. Cox DR. Regression models and life tables (with discussion). J Stat Soc B 1972; 34: 187-220.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
19. Dunn SE, Hardman RA, Kari FW, Barrett JC. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL 100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997; 57: 2687-93.
20. Resnicoff M, Burgaud JL, Rotman HL, Abraham D, Baserga R. Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res 1995; 55: 3739-41.
21. Rubin R, Baserga R. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest 1995; 73: 311-31.
22. Sell C, Baserga R, Rubin R. Insulin-like growth factor I (IGF- I) and the IGF I receptor prevent etoposide-induced apoptosis. Cancer Res 1995; 55: 303-6.
23. Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor I in elderly men and women. The Rancho Bernardo study. Am J Epidemiol 1997; 145: 970-6.
24. Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, et al. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol 1994; 41: 351-7.
25. Silvestrini R, Benini E, Veneroni S, et al. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 1996; 14: 1604-10.
26. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996; 156: 1511-6.
27. Bubendorf L, Sauter G, Moch H, et al. Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 1996; 148: 1557-65.
28. Wang TT, Phang JM. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 1995; 55: 2487-9.
29. Perry RR, Kang Y, Greaves BR. Relationship between tamoxifen-induced transforming growth factor beta 1 expression, cytostatis and apoptosis in human breast cancer cells. Br J Cancer 1996; 74: 993-4.